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INTRODUCTION 
 
Cardiovascular disease affects at least 1 in 3 Americans, and is the 
leading cause of death in the United States (Roger et al., 2011).  There are many 
risk factors that contribute to cardiovascular disease, and a vast amount of 
research has focused on the mechanisms that have contributed to initiation and 
progression of the disease.  Increasing age, a major risk factor, is associated 
with increases in reactive oxygen species (ROS), which is thought to contribute 
to the development of age-related cardiovascular disease.  Previous work in 
aged humans and animals has shown that NAD(P)H oxidase (Nox) contributes to 
age-related endothelial dysfunction and vascular fibrosis, and that reducing 
superoxide dismutase 1 (SOD1, cytosolic), SOD2 (mitochondrial), or SOD3 
(extracellular) worsens endothelial function with aging (Brown, Chu, Lund, 
Heistad, & Faraci, 2006; Brown, Didion, Andresen, & Faraci, 2007; Didion, 
Kinzenbaw, Schrader, & Faraci, 2006; Didion et al., 2002; Fukai, 2009; Lund, 
Chu, Miller, & Heistad, 2009). In vitro experiments also suggest that, once 
initiated, ROS production may self-perpetuate (ROS-induced ROS-release) and 
further accelerate development of endothelial dysfunction and disease (A. E. 
Dikalova, Bikineyeva et al., 2010).   
There is mounting of evidence that suggests sirtuin deacetylases play a 
major role in protecting against a number of age-related diseases, and may 
protect against vasomotor dysfunction with aging.  For example, SIRT6-deficient 
mice have profound reductions in bone mineral density, exaggerated 
   2 
 
kypholordosis, and a dramatically shortened lifespan compared to their wild-type 
littermates (Mostoslavsky et al., 2006).  Furthermore, the observation that SIRT1-
dependent deacetylation of endothelial nitric oxide synthase is essential for 
eNOS activation provides a more direct role of sirtuins in the regulation of 
vasomotor function.  How sirtuin expression levels change with aging in different 
cardiovascular tissues, however, remains largely unknown.     
One of the most common consequences of aging is stiffening of the aorta 
and aortic valve secondary to calcification and fibrosis.  We have previously 
shown that valvular calcification is strongly associated with increases in oxidative 
stress and reductions in antioxidant defense mechanisms in humans (Miller, Chu 
et al., 2008).  Several studies have shown that the balance between oxidative 
stress and nitric oxide bioavailability is an important determinant of vascular and 
valvular calcification in vitro (Miller, Chu et al., 2008; Weiss, Ohashi, Miller, 
Young, & Heistad, 2006; Yoshii et al., 2006).  Furthermore, expression and 
activity of a number of aging-related genes has been shown to be regulated by 
oxidative stress.  We are, however, not aware of data experimentally determining 
this link in vivo. 
Thus, the aims of the current study were as follows: 1) to determine 
whether reducing mitochondrial antioxidant, manganese superoxide dismutase 
(MnSOD), results in maladaptive changes in pro- and anti-oxidant gene 
expression due to ROS-induced ROS-release with aging, 2) to determine 
whether reducing mitochondrial antioxidant, MnSOD, exacerbates reductions in 
aging-associated gene expression, sirtuins, and 3) to examine the consequences 
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of reducing mitochondrial antioxidant, MnSOD, on aortic and aortic valve 
function.  The overall aim of this work was to test two over-arching working 
hypotheses.  First, that molecular changes associated with aging are markedly 
different between aorta and aortic valve.  Second, that reducing mitochondrial 
antioxidant, MnSOD, would increase oxidative stress and reduce nitric oxide 
bioavailability, exaggerate reductions in longevity-related genes, and ultimately 
accelerate age-related aortic and aortic valve dysfunction. 
The specific hypotheses we tested in the current work can be broken 
down into three categories: 1) changes in aorta with aging and/or MnSOD 
deficiency, 2) changes in aortic valve with aging and/or MnSOD deficiency, and 
3) differences between aorta and aortic valve with aging and/or MnSOD 
deficiency.   
Hypotheses 
Changes in aorta with aging and/or MnSOD deficiency 
Hypothesis 1: Overall antioxidant capacity will be reduced and pro-oxidant gene 
expression will be increased with aging in aorta.   
Hypothesis 2: Reduction of MnSOD in aorta will increase oxidative stress and 
NAD(P)H oxidase isoform expression due to the initiation of ROS-induced ROS-
release.     
Hypothesis 3: Sirtuin expression will be significantly reduced in aorta with 
increasing age, and these reductions will be exacerbated in MnSOD-deficient 
mice.   
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Hypothesis 4: Increasing age will exacerbate endothelial dysfunction in MnSOD-
deficient mice due to further amplification of ROS-induced ROS-release from 
age-related mitochondrial dysfunction and age-related increases in NAD(P)H 
oxidase expression .   
Changes in aortic valve with aging and/or MnSOD deficiency 
Hypothesis 5: Increasing age will significantly reduce overall antioxidant capacity 
and antioxidant transcription factor expression and an increase of oxidative 
stress in aortic valve.   
Hypothesis 6:  Reduction of MnSOD in aortic valve will increase NAD(P)H 
oxidase isoform expression due to the initiation of ROS-induced ROS-release.     
Hypothesis 7: Sirtuin expression will be significantly reduced in aortic valve with 
increasing age, and losses of MnSOD will exaggerate these effects.   
Hypothesis 8: Increasing age will exacerbate aortic valve dysfunction in MnSOD-
deficient mice due to further amplification of ROS-induced ROS-release from 
age-related mitochondrial dysfunction and age-related increases in NAD(P)H 
oxidase expression in the valve.   
Differences between aorta and aortic valve with aging and/or MnSOD 
deficiency 
Hypothesis 9: Reductions in expression of antioxidants and antioxidant 
transcription factors with aging will be greater in aortic valve compared to aorta. 
Hypothesis 10: Reductions of MnSOD will initiate ROS-induced ROS-release in 
both aorta and aortic valve, and these effects will be exacerbated by aging in 
both tissues.   
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Hypothesis 11: Reductions in sirtuin expression with increasing age will be 
greater in aortic valve compared to aorta.    
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LITERATURE REVIEW 
Endothelial Function 
Endothelial cells (EC) line the lumen of arteries as a monolayer of cells 
and play a major role in the regulation of cardiovascular homeostasis.  Within the 
walls of the vessels there is a delicate balance between nitric oxide (NO) 
bioavailability and levels of reactive oxygen species (ROS).  NO bioavailability is 
largely determined by the production of NO via nitric oxide synthase (NOS).  
Furchgott and Zawadzki are credited with the discovery of NO and its role as a 
signaling molecule between endothelial cells and vascular smooth cells acting as 
primarily as an endothelium-derived relaxing factor (Furchgott, Carvalho, Khan, & 
Matsunaga, 1987).  Briefly, NO produced in EC is then transported to the 
neighboring smooth muscle cells, where NO interacts with soluble guanylate 
cyclase (sGC) and guanosine triphosphate (GTP) to produce cyclic guanosine 
monophosphate (cGMP).  Ultimately, cGMP will signal vasorelaxation in smooth 
muscle cells (Thomas, Witting, & Drummond, 2008).  This process will continue 
as long as there is ample amount of NO bioavailability in the vasculature. 
   Reactive oxygen species (ROS) are natural cellular byproducts and two 
main sources of ROS are NAD(P)H oxidases and mitochondria (Finkel & 
Holbrook, 2000).   The balance between NO bioavailability and ROS is preserved 
by antioxidant defense systems (i.e. catalase, superoxide dismutases), however, 
several investigators have suggested that the major driver for an increased risk 
of age-related diseases is an increase in reactive oxygen species (ROS) (Csiszar 
et al., 2002; Forstermann, 2010; Hamilton, Brosnan, Al-Benna, Berg, & 
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Dominiczak, 2002; Lakatta & Schulman, 2004; Schulz, Jansen, Wenzel, Daiber, 
& Munzel, 2008; Wilcox et al., 1997). ROS are efficient at inactivating nitric oxide 
(NO), which can subsequently lead to further production of ROS (Forstermann, 
2010).  The term “oxidative stress” is defined as an increase production of ROS 
which exceeds the antioxidant defense systems and contributes to cellular 
toxicity (Drummond, Selemidis, Griendling, & Sobey, 2011; Forstermann, 2010).  
Oxidative stress, collectively, inhibits NO production and decreases NO 
bioavailability leading to various age-related cardiovascular diseases. 
Nitric Oxide Synthases 
 Nitric oxide synthase function is the conversion of L-arginine to L-citrulline 
and NO in order to promote endothelium-dependent relaxation.  The structure of 
NOS is a homodimer which is comprised of a reductase domain (C-terminal) and 
oxygenase domain (N-terminal).  The reductase domain is the binding site of 
NADPH, FAD, and FMN.  Tetrahydrobiopterin (BH4), heme, L-arginine, and zinc 
ion bind to the oxygenase domain.  In the presence of intracellular calcium 
(Ca2+), calmodulin also binds between the two domains (Andrew & Mayer, 1999; 
Forstermann, 2010).   
There are three distinct NOS isoforms each possessing unique 
responsibilities in the body.  Endothelial NOS (eNOS) and neuronal (nNOS) are 
classified as Ca2+-dependent, whereas, inducible NOS (iNOS) activity is Ca2+-
independent and activated by cytokines and other inflammatory markers (Andrew 
& Mayer, 1999).  However, eNOS activity has also been shown to be induced in 
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Ca2+-independent environments, particularly following the phosphorylation of 
residues on the eNOS structure (Forstermann, 2010).   Location of the isoforms 
in the body is also specific to each isoform.  For instance, nNOS is largely 
expressed in nervous tissue and also skeletal muscle (Andrew & Mayer, 1999).  
eNOS expressed in endothelial cells is highly involved in the generation of NO-
dependent relaxation in blood vessels (Andrew & Mayer, 1999).  Similarly to that 
of eNOS, iNOS plays a critical role in the cardiovascular system especially in 
disease states.  Induced by inflammatory mediators, iNOS impairs NO production 
by eNOS via its own high output of NO (Kessler, Bauersachs, Busse, & Schini-
Kerth, 1997).  Overall, each isoform presents unique expression and activity in 
the body.   
 NO biosynthesis begins at the reductase domain where NADPH donates 
electrons.  Calmodulin binds to NOS due to calcium-induced binding to NOS 
(Forstermann, 2010).  Calmodulin modulates the flow of electrons and the 
initiation of electron transfer from the C-terminal to N-terminal.  Electrons flow to 
the heme center.  Important NOS cofactors L-arginine and BH4 are bound to the 
oxygenase domain.  The zinc ion is also important cofactor for NOS because it 
has been found that it may help with the stereospecificity of BH4 binding (Andrew 
& Mayer, 1999).  L-arginine is then hydroxylated from L-arginine to NG-hydroxy-L-
arginine and is quickly oxidized to L-citrulline and NO. Largely, NO biosynthesis 
is increased with the presence of Ca2+ because of the increase binding and flow 
of electrons by calmodulin.  However, in some states such as increased shear 
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stress of blood flow, estrogens, insulin, or bradykinin, has been found to initiate 
NO production when there are no changes in Ca2+ levels (Forstermann, 2010).  
This may be explained by the phosphorylation of multiple sites within NOS that 
induces the increase of flow of electrons from the reductase domain to the 
oxygenase domain (Andrew & Mayer, 1999; Forstermann, 2010).  Collectively, 
production of NO can be mediated by either Ca2+ dependent or Ca2+ independent 
mechanisms.     
Essential NOS cofactors 
  Endothelial function is highly dependent on proper NO production from 
NOS and in turn NOS is highly dependent on the presence of the cofactors, BH4 
and L-arginine.  BH4 and L-arginine are the cofactors that are essential to the 
production of NO.  However, disruption of cofactor bioavailability can significantly 
impair NO production leading to decreased NO bioavailability and ultimately 
endothelial dysfunction.  
 BH4 bioavailability is regulated by multiple factors such as positive 
regulation by GTP-cyclohydrolase I (GTPCH I) and negative regulation by ROS.  
As an essential cofactor, BH4 promotes L-arginine binding to the NOS heme iron 
binding site (Touyz & Briones, 2011).  Binding of BH4 to NOS also contributes to 
stabilization of the NOS dimer formation (Touyz & Briones, 2011).  However, BH4 
is easily oxidized to its inactive form BH2 by reactive oxygen species, which can 
lead to reduced bioavailability of BH4.  In disease states where reactive oxygen 
species levels are high, BH4 is readily oxidized to BH3· by peroxynitrite (ONOO
-), 
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before further oxidation to BH2.  ONOO
- is produced by the interaction between 
superoxide (O2·
-) and NO (Forstermann, 2010).  Increased levels of ONOO- 
significantly reduces BH4 levels therefore, leading to impaired NOS function.   
Attenuation of BH4 levels can also lead to the “uncoupling” of NOS.  
Uncoupled NOS is unable to produce NO, but rather generates O2·
- and 
furthering ROS production (Forstermann, 2010; Landmesser et al., 2003).  
Collectively, the presence of BH4 is an essential component to the production of 
NO and ultimately endothelial function.   
 L-arginine is endogenously inhibited by asymmetric dimethyl-L-arginine 
(ADMA), blocking L-arginine binding to NOS.  However, this inhibition is tightly 
regulated by the presence of dimethylaminohydrolase (DDAH), which is 
responsible for the degradation of ADMA.  ADMA and DDAH are redox sensitive, 
and in the presence of oxidative stress DDAH levels are reduced and ADMA 
levels are increased (Goumas, Tentolouris, Tousoulis, Stefanadis, & Toutouzas, 
2001).  This imbalance between ADMA and L-arginine functionally creates an L-
arginine deficient environment, resulting in NOS dysfunction (Forstermann, 2010; 
Goumas et al., 2001).   
Hydrogen Peroxide as an Endothelium-Derived Hyperpolarizing Factor 
 Hydrogen Peroxide (H2O2) has been implicated to be an endothelium-
derived hyperpolarizing factor (EDHF) (Shimokawa & Matoba, 2004).  In the 
presence of superoxide, NO bioavailability is reduced and NO-dependent 
endothelial function is impaired (Forstermann, 2010).  Superoxide is degraded 
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either spontaneously or by superoxide dismutases (SODs) to H2O2.  In various 
studies H2O2 can alternatively induce vascular relaxation (Cherry, Omar, Farrell, 
Stuart, & Wolin, 1990; Iesaki, Gupte, Kaminski, & Wolin, 1999; Sobey, Heistad, & 
Faraci, 1997).  It is believed that H2O2 originates from the endothelial cell and 
diffuses to the vascular smooth muscle cell where it activates K+ channels to 
hyperpolarize the vessel (Edwards, Dora, Gardener, Garland, & Weston, 1998; 
Edwards et al., 2000; Matoba et al., 2000).   The production of superoxide by 
eNOS may be a significant source of the H2O2 contributing to H2O2-derived 
EDHF, as Matoba et al have previously shown that eNOS knockout mice 
significantly had reduced H2O2-derived EDHF responses (Shimokawa & Matoba, 
2004).  Collectively, increases in H2O2 production may be an important 
compensatory mechanism under conditions of reduced NO bioavailability.   
Prostaglandins    
Prostaglandins also contribute to endothelium derived relaxing factors, 
specifically prostacyclin (PGI2).  Production of PGI2 is mediated by 
cyclooxygenase (Wilcox et al.) (Wilcox et al.) enzyme.  COX metabolizes 
arachidonic acid to produce PGI2 (Rosolowsky & Campbell, 1993).  PGI2 then 
travels to the vascular smooth muscle where it acts on cyclic-AMP in the vascular 
smooth muscle to induce relaxation (Shimokawa & Matoba, 2004).  It has been 
shown that the inhibition of COX via indomethacin administration significantly 
impairs endothelial relaxation, suggesting that the formation of PGI2 via COX is 
critical to endothelium-dependent relaxation (Rosolowsky & Campbell, 1993).   
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Sources of ROS 
ROS is produced by a variety of sources in the body, however, there are 
four main producers that predominate the ROS production in the vascular walls: 
NAD(P)H oxidase, mitochondrial respiration, xanthine oxidase, and uncoupled 
eNOS (A. E. Dikalova, Bikineyeva et al., 2010; Thomas et al., 2008; Touyz & 
Briones, 2011).   It has been shown that these ROS producing enzymes may act 
on one another to initiate a feed-forward phenomenon that will potentiate 
oxidative stress and impairment of endothelial function (S. Dikalov, 2011; A. E. 
Dikalova, Bikineyeva et al., 2010; Landmesser et al., 2003).     
NAD(P)H Oxidases 
Nicotinamide adenine dinucleotide phosphate (NAD(P)H)-oxidase (Nox) 
family of enzyme complexes is comprised of seven different isoforms 
(Drummond et al., 2011; Forstermann, 2010; Thomas et al., 2008).   Nox are 
enzymes that are found in cells such as endothelial cells and vascular smooth 
muscle cells.  However, Nox is not limited to endothelial and vascular smooth 
muscle cells, but also play a major role in the immune defenses such as 
phagocytosis (Drummond et al., 2011).   In general, the main function of Nox 
enzymes is to produce ROS (Drummond et al., 2011), and currently is the only 
known family of enzymes to have ROS production as its only function.  
Depending on the Nox isoform, superoxide (O2·) or hydrogen peroxide (H2O2) is 
the major product from Nox.  In the vasculature, four of the seven Nox isoforms 
are present: Nox1, Nox2, Nox4, and Nox5 (Drummond et al., 2011).  
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Furthermore, Nox1, Nox4, and Nox5 are present in vascular smooth muscle 
cells, but Nox2 is not present (Drummond et al., 2011; Thomas et al., 2008).   It 
has been found that each Nox isoform in vasculature plays unique role in the 
development of impaired endothelial function. 
Nox1 is found in both endothelial cells and vascular smooth muscle cells, 
however, its role in vascular smooth muscle cells (VSMC) biology is well 
understood compared to its role in endothelial cell biology (Drummond et al., 
2011).  Atherosclerotic animal models have provided a vast amount of 
knowledge about Nox1 and its role in vascular remodeling, increased ROS 
production, neointimal formation (Bengtsson, Gulluyan, Dusting, & Drummond, 
2003; Niu et al., 2010; Sheehan et al., 2011).  Production of superoxide by Nox1 
is found to be upregulated and contribute to hypertension in animal models 
(Akasaki et al., 2006; S. I. Dikalov et al., 2008; A. Dikalova et al., 2005).  
Collectively, Nox1 is found largely in the vascular smooth muscle and potentiates 
ROS production in hypertension and atherosclerotic lesions.   
Nox4 research has a rather controversial background and is hard to 
determine its exact role in VSMC.  Similar to other Nox isoforms, the majority of 
the evidence suggests that it plays a detrimental role in the vasculature.  
Pedruzzi et al has demonstrated that Nox4-derived H2O2 induces oxidative stress 
in aortic vascular smooth muscle cells (Pedruzzi et al., 2004).  They also showed 
that this oxidative stress leads to cell death and contributes to the pathogenesis 
of atherosclerosis (Pedruzzi et al., 2004).  However, some work has suggested 
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that Nox4 may have a protective role in the vasculature, such as promoting 
endothelial cell survival (Basuroy, Tcheranova, Bhattacharya, Leffler, & 
Parfenova, 2010; Datla et al., 2007).   The conflicting data regarding Nox4 and its 
potential opposing role in different cell types makes it difficult to fully understand 
the net effect of Nox4 activation in the vasculature.   
Nox2 only found in EC and not in VSMC has been characterized as the 
mediator of endothelial injury.  Composed of necessary subunits p47phox and 
p22phox, Nox2 expression is increased in the presence of pro-inflammatory 
stimuli (S. Dikalov, 2011; Drummond et al., 2011).  It has been well established, 
in angiotensin II induced hypertension, is the causation of the upregulation of 
Nox2 and also Nox1 in vasculature (S. Dikalov, 2011; Drummond et al., 2011).  
Numerous investigators have improved vascular function by administering 
apocynin, an NAD(P)H oxidase inhibitor (Bendall et al., 2007; Rey, Cifuentes, 
Kiarash, Quinn, & Pagano, 2001).  However, Rey et al was the first group to 
demonstrate that specifically inhibiting Nox2, gp91 ds-tat peptide, attenuates 
vascular oxidative stress and reduces systolic blood pressure in hypertensive 
mouse model (Rey et al., 2001).  It has also been well established in aging 
models that inhibition of Nox2 improves endothelial function (Csiszar et al., 2002; 
Donato et al., 2007; Hamilton et al., 2002); providing evidence that Nox2 
mediates age-induced endothelial dysfunction.  The fact that inhibition of Nox2 
improves endothelial function strongly suggests that Nox2 plays a pivotal role in 
the pathophysiology of multiple vascular diseases.    
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Mitochondria 
The mitochondria are often considered as the “energy house” of the cell.  
Largely, mitochondria are known for its production of adenosine-5’-triphosphate 
(ATP), however, the byproduct—ROS—is often given little attention.  This is 
largely due to the fact that endothelial cells have a low metabolic rate (S. Dikalov, 
2011; Y. Zhang et al., 2009).  It has been well established, recently, that 
mitochondria is one of the main sources of ROS in the vasculature (S. Dikalov, 
2011; D. X. Zhang & Gutterman, 2007).  Consequently, the paradigm has shifted 
from NAD(P)H oxidase being the sole driver of ROS in endothelium, to 
examining the effects of mitochondria-derived ROS in the vasculature (S. 
Dikalov, 2011). 
The electron transport chain is the origin of ROS in the mitochondria, 
where the four main complexes transfer electrons to assemble ATP (S. Dikalov, 
2011; D. X. Zhang & Gutterman, 2007).  Briefly, complex I transfers electrons 
from nictotinamide adenine dinucleotide (NADH) to complex II.  Ubiquinone 
mediates the flow of electrons to complex III.  Finally, electrons pass through 
complex IV to form H2O and then pumps H+ into the inter membrane (S. Dikalov, 
2011).  The respiration process of the mitochondria is the known source of ROS.  
Predominantly, complex I and complex III have been recognized as primary 
sources of ROS in the electron transport chain (D. X. Zhang & Gutterman, 2007).  
These two complexes “leak” superoxide (O2·
-) on the matrix side of the 
mitochondria.  It has been recently shown that complex II may also form ROS via 
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a process called reverse electron transport, however this is not completely 
understood (Ackrell, Kearney, & Mayr, 1974; Lambert, Buckingham, Boysen, & 
Brand, 2008).  Once superoxide is produced in the mitochondria it is not easily 
diffused across in the cell membrane, leaving the mitochondria very susceptible 
to DNA damage, signaling of cell death (apoptosis), and other ROS-induced 
effects (D. X. Zhang & Gutterman, 2007).  In order to reduce the accumulation of 
ROS the mitochondria has a “built in” antioxidant defense system.   
Manganese superoxide dismutase (MnSOD), localized only in the 
mitochondrial matrix, and scavenges O2·
- and reduces it to H2O2.  Once O2·
- is 
converted to H2O2 by MnSOD it can readily diffuse across the cell membrane (D. 
X. Zhang & Gutterman, 2007).  However, increased mitochondrial ROS 
production as is the case in the presence of mitochondrial diseases or aging, can 
lead to oxidative stress in the mitochondria and impairment of ATP production 
and other adverse effects (Ballinger, 2005).   Recently, it has also been shown 
mitochondrial oxidative stress can act upon or signal other external ROS 
production, such as NAD(P)H oxidase (S. Dikalov, 2011; A. E. Dikalova, 
Bikineyeva et al., 2010).   
Xanthine Oxidase 
Xanthine oxidase is derived from irreversible proteolysis of xanthine 
dehydrogenase (XDH) (Forstermann, 2010; McNally, Saxena, Cai, Dikalov, & 
Harrison, 2005).  Xanthine oxidase (XO) reduces xanthine and hypoxanthine 
substrates to produce O2·
- and H2O2 (McNally et al., 2005).  Studies have shown 
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that inhibition of XO improves endothelial function in patients (Ohara, Peterson, & 
Harrison, 1993).  However, McNally et al showed that production of ROS by XO 
is highly redox-sensitive, and specifically dependent of NAD(P)H oxidase 
expression (McNally et al., 2005).    
Uncoupled eNOS  
eNOS can be in two functional forms, coupled and uncoupled.  Coupled 
eNOS produces the protective NO, whereas uncoupled eNOS manufactures O2·
- 
that promotes deleterious effects on vasculature.   The main determinant of 
coupled eNOS is BH4 bioavailability.  High levels of BH4 contribute to the 
stabilization of dimer structure and the coupled state of eNOS to synthesize NO 
(Montezano & Touyz, 2011).  However, a reduction of BH4 bioavailability 
influenced by oxidative stress is due to the increase in ONOO- formation, 
reductions of GTPCH expression, and oxidation to the inactive form, BH2.  The 
homodimer structure is affected by reductions of BH4, which decreases the 
stabilization of the dimer and prevents L-arginine to bind to the oxygenase 
domain (Moens & Kass, 2006; Montezano & Touyz, 2011).  Inability for L-
arginine to bind, electrons that are transferred through the haem are now 
donated to molecular O2 to produce O2·
- (Moens & Kass, 2006; Montezano & 
Touyz, 2011).  Change in the dimer structure prevents L-arginine binding to 
eNOS causing electrons to be donated to molecular O2 with an end product of 
O2·
- (Montezano & Touyz, 2011).   
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Antioxidant Defenses 
Build up ROS in the cell can contribute to numerous cellular deleterious 
changes such as, DNA damage, cell growth, and cell apoptosis (Finkel & 
Holbrook, 2000; Podlutsky, Ballabh, & Csiszar, 2010; Schiffrin, 2008; Touyz & 
Briones, 2011).   Through the course of evolution the body has developed an 
antioxidant defense system to break down ROS into reduced forms and promote 
vascular homeostasis.  Superoxide dismutases and hydrogen peroxide-
degrading enzymes are responsible for this, for instance, superoxide dismutases 
break down O2·
- into H2O2 and O2, and hydrogen peroxide-degrading enzymes 
reduce H2O2 into H2O.  However, each enzyme has its own unique key 
differences that contribute to vascular homeostasis and to preserve NO 
bioavailability .   
SOD’s 
There are three different isoforms of superoxide dismutases (SOD): 
copper-zinc SOD (CuZnSOD), located in the cytoplasm; extracellular SOD 
(ecSOD), present in the extracellular matrix; and manganese SOD (MnSOD), 
found strictly in the mitochondria (Forstermann, 2010).  Genetically reducing 
either CuZnSOD, ecSOD, or MnSOD in animals has found to increase oxidative 
stress and decrease NO bioavailability in vasculature (Didion et al., 2006; Didion 
et al., 2002; Gongora et al., 2006; Jung et al., 2003; Y. Zhang et al., 2009).  It is 
also important to note that reducing one SOD isoform does not cause a 
compensatory increase in the other SOD isoform expressions, and that 
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overexpressing any one SOD isoform may stave off pathophysiologies 
associated with aging, but does not extend lifespan (Faraci & Didion, 2004; 
Perez et al., 2009).  Furthermore, of the three SOD isoforms, MnSOD is essential 
to life.  Mitochondria is a major source of ROS, consuming nearly 5% of all 
molecular O2 and converting it to O2·
- due to the electron transport chain (Faraci 
& Didion, 2004).   Therefore, the mitochondria are highly susceptible to oxidative 
damage and MnSOD is the first line of defense to reduce ROS accumulation.  Li 
et al have demonstrated the importance of MnSOD is to life by globally knocking 
out MnSOD.  It was found that these mice die shortly after birth due to the 
development of dilated cardio myopathy (Y. Li et al., 1995).  
Transcription factors and external/internal stimuli are responsible for the 
regulation of SOD isoforms expression levels.  Transcription factor protein, NF-
κB, an important protein in inflammation and immunity defenses, promotes cell 
survival in the presence of ROS (Morgan & Liu, 2010).  NF-κB has been found to 
induce and mediate MnSOD and CuZnSOD expression (Dhar, Tangpong, 
Chaiswing, Oberley, & St Clair, 2011; Rojo, Salinas, Martin, Perona, & Cuadrado, 
2004; Zelko, Mariani, & Folz, 2002).  MnSOD and CuZnSOD also share common 
transcription factors specificity protein-1 (Sp1) and activator protein-1 (AP1) (M. 
Li, Chiu, Mossman, & Fukagawa, 2006; Zelko et al., 2002).  MnSOD is also 
positively regulated by transcription factor Forkhead box class O-3a (FOXO3a) 
(M. Li et al., 2006).  ecSOD shares very similar genomic structure to that of 
CuZnSOD, however, ecSOD transcription factors are different than that of 
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CuZnSOD and MnSOD (Zelko et al., 2002).  ecSOD has sites for Kruppel-like 
and Ets-family transcription factors, but little research has focused on the 
functional importance of these ecSOD transcription factors (Zelko et al., 2002).   
Transcription factor activation and binding are promoted by numerous 
stimuli in and outside the cell.  CuZnSOD is highly induced by noxious stimuli 
such as hydrogen peroxide and induction of oxidative stress by paraquat 
treatments (Yoo, Chang, & Rho, 1999; Zelko et al., 2002).  Instead MnSOD and 
ecSOD expression levels are regulated by pro-inflammatory cytokine stimuli.  
Tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), and interferon-γ 
(IFN-γ) have been shown to increase MnSOD expression in vascular smooth 
muscle cells (VSMC) (Stralin & Marklund, 2000; Zelko et al., 2002).  IFN-γ has 
also been shown to upregulate ecSOD VSMC, however, expression is down 
regulated in the presence of TNF-α (Stralin & Marklund, 2000; Zelko et al., 2002).    
Collectively, stimulation by external/internal factors initiates the activity of 
transcription factors to promote the antioxidant defenses.   
Hydrogen peroxide-degrading enzymes 
Hydrogen peroxide (H2O2) is not a charged molecule like superoxide, 
however, it is still considered to be a reactive oxygen species.  Its classification 
as a ROS is largely due to the fact H2O2 is easily converted to a hydroxyl group 
(OH·) via the Fenton reaction (Nordberg & Arner, 2001).  OH· accumulation leads 
to lipid peroxidation and DNA/protein damage (Nordberg & Arner, 2001).  
Therefore, there are three main enzymatic proteins (catalase, glutathione 
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peroxidase, and peroxiredoxins) that degrade H2O2 to H2O and O2 to reduce the 
likelihood of the conversion to the highly toxic OH·.   
Catalase 
 Catalase, a heme-containing homotetrameric protein, is one of the main 
hydrogen peroxide-degrading enzymes.  Catalase is primarily localized in 
peroxisomes, however, catalase has been found in mitochondria of 
cardiomyocytes (Ho, Xiong, Ma, Spector, & Ho, 2004; Radi et al., 1991).  Two 
major reactions constitute catalase activity: catalytic mode and peroxidatic mode 
(Chance, Sies, & Boveris, 1979; Ho et al., 2004).  At high levels of concentration 
H2O2, a molecule of H2O2 reacts with the heme group of catalase to form 
compound I.  Compound I then interacts with a second molecule of H2O2 to yield 
H2O and O2 (Chance et al., 1979; Ho et al., 2004), therefore, it is necessary to 
have two molecules of H2O2 to degrade H2O2.  However, at low concentrations of 
H2O2 compound I can oxidize alcohols via the peroxidation reaction.  This 
suggests that the peroxidation activity is favorable at low H2O2 concentration 
(Boveris, Oshino, & Chance, 1972; Keilin & Hartree, 1949).  Catalase activity is 
not only regulated by H2O2 concentration, but also various exogenous and 
endogenous stimuli both positive and negative.  For instance, increase in Nox4 
via TGF-β signaling has been shown to down regulate catalase activity 
(Michaeloudes, Sukkar, Khorasani, Bhavsar, & Chung, 2011), whereas, Foxo3a 
stimulates catalase transcription (Bonekamp, Volkl, Fahimi, & Schrader, 2009).    
Glutathione Peroxidase 
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 Hydrogen peroxide-degrading enzyme, glutathione peroxidase (Gpx), is 
believed to reduce over 70% of all H2O2 produced in the cell due to higher affinity 
to H2O2 compared to catalase (Stanczyk, Gromadzinska, & Wasowicz, 2005).  
The main source of production of Gpx is in the liver, however, Gpx is produced in 
all cells (Hammond, Lee, & Ballatori, 2001; Stanczyk et al., 2005).   Localized to 
the cytosol of the cell, but also located in the mitochondria (Rhee, Chae, & Kim, 
2005; Stanczyk et al., 2005), it is largely responsible for the degradation of H2O2 
and has been found to play a crucial role in the regulation of apoptosis and 
inhibition of lipid peroxidation (Hammond et al., 2001; Owen & Butterfield, 2010; 
Stanczyk et al., 2005).  In order to reduce H2O2 to H2O and O2, Gpx oxidizes 
glutathione (GSH) to glutathione disulfide (GSSG).  GSSG is quickly reduced 
back to GSH by the enzyme glutathione reductase at the expense of NADPH.  
GSH/GSSG ratio is often indicative of oxidative stress and overall cell health.  In 
healthy cells, reduced GSH constitutes more than 90% of the cell GSH present, 
whereas GSSG makes up less than 10%.  However, when oxidative stress is 
increased this ratio is reduced (Hammond et al., 2001; Owen & Butterfield, 2010; 
Stanczyk et al., 2005).      
Peroxiredoxin 
 Peroxiredoxin (Prx), originally termed thioredoxin peroxidase, is the most 
recently discovered protein able to reduce H2O2 along with organic hydrogen 
peroxides and peroxynitrite (Immenschuh & Baumgart-Vogt, 2005; Nordberg & 
Arner, 2001).  In brief, Prx’s reactive cysteine residues catalyze the degradation 
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of H2O2 by oxidizing thioredoxin (Trx) as the electron donor to form H2O and O2 
(Zhu, Santo, & Li, 2012).  The oxidized Trx is then reduced back by thioredoxin 
reductase (Zhu et al., 2012).  Six known isoforms comprise the Prx family: Prx I, 
Prx II, Prx III, Prx IV, Prx V, and Prx VI.  Prx I is the most widely distributed in 
tissue and also at the cellular level.  Prx V is the second most widely distributed 
Prx, and is found in cytoplasm, mitochondria, and peroxisomes.  Prx II is 
localized in the nucleus and cytoplasm, and Prx IV in the extracellular space and 
lysosomes.  Prx III and Prx VI are the only Prx isoforms that have been found to 
be specifically localized to one area—mitochondria and cytoplasm, respectively 
(Immenschuh & Baumgart-Vogt, 2005).  Prx gene expression, explicitly Prx I, is 
induced by lipopolysaccharide (LPS) and heavy metals in liver tissue 
macrophages and cultured hepatic cells, respectively (Immenschuh & Baumgart-
Vogt, 2005).  Transcriptionally, Prx gene expression is regulated by Nrf2, a key 
gene regulator in oxidative stress environments (Immenschuh & Baumgart-Vogt, 
2005; Zhu et al., 2012).    
ROS-Induced ROS-Release Phenomenon 
It has been found by many investigators that cytoplasmic ROS production 
can activate mitochondrial-derived ROS, vice versa, and may begin a vicious 
cycle contributing to ROS accumulation in the cell (A. E. Dikalova, Bikineyeva et 
al., 2010; Kimura et al., 2005).  Dikalova et al has investigated this ROS-induced 
ROS-release (RI-RR) phenomenon in an angiontensin (Ang) II model.  Ang II has 
been shown to upregulate Nox2 (Mehta & Griendling, 2007; Mollnau et al., 2002; 
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Seshiah et al., 2002; Touyz & Briones, 2011) in rats and mice, therefore, this 
increase in ROS production will lower NO bioavailability.  Research has shown 
that Nox2-dervied ROS activates mitoKATP, a regulated potassium channel of the 
mitochondria.  MitoKATP activation causes a rapid influx of K
+ and signals an 
enhancement of mitochondrial ROS production (S. Dikalov, 2011; Krenz et al., 
2002).  This finding suggests that there is a crosstalk occurring between 
NAD(P)H oxidases and mitochondria which perpetuate ROS production (see 
Figure 1).  Dikalova et al (2010) has further demonstrated this crosstalk between 
these two ROS generating systems using both in vivo and in vitro models.  It was 
shown that Ang II treated cells increased NAD(P)H oxidase activity, (consistent 
with previous findings of upregulation of NAD(P)H oxidase due to Ang II (Mehta 
& Griendling, 2007; Mollnau et al., 2002; Seshiah et al., 2002; Touyz & Briones, 
2011)), and NAD(P)H oxidase activity was augmented even further in cells with 
MnSOD deficiency.  However, cellular levels of ROS were nearly abrogated with 
treatment of mitoTEMPO, a specific mitochondrial superoxide scavenger.  
Collectively, this finding provides evidence that mitochondria-derived and 
NAD(P)H oxidase-derived ROS augment one another through a feed forward 
mechanism.  This group also observed impaired aortic endothelial relaxation to 
acetylcholine in C57 mice treated with Ang II, however, Ang II treated vessels 
incubated with mitoTEMPO observed improved relaxation to basal levels (A. E. 
Dikalova, Bikineyeva et al., 2010).  Largely, the body of evidence to support this 
RI-RR phenomenon has been performed in in vitro, and we are only beginning to 
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understand the role of RI-RR in vivo.  Currently, there is lack of investigation 
examining the effects RI-RR has on endothelial function and aortic valve 
function in unstressed conditions, and whether or not RI-RR is exacerbated 
with increasing age.   
Key Interactions between NO and ROS 
 Accumulation of ROS has significant negative effects on NO bioavailability 
which ultimately leads to endothelial dysfunction.  Production of superoxide has 
been found to have deleterious implications on overall endothelial health, such as 
the formation of peroxynitrite (ONOO-).  ONOO- forms almost instant when NO 
and O2·
- are just a few microns from each other (Pacher, Beckman, & Liaudet, 
2007) and does not need an enzyme in order for this reaction to happen.  Modest 
increases of NO and O2·
- production will cause an exponential increase of 
ONOO- formation (Pacher et al., 2007), which will perpetuate the imbalance 
between ROS and NO.  Accumulation of ROS impairs NO bioavailability by 
interfering the ability for DDAH to break down ADMA.  The inability to reduce 
ADMA levels creates a functional blockade of the essential NOS cofactor, L-
arginine, therefore leading to a decrease of NO bioavailability.  ONOO- also 
oxidizes BH4 to its inactive form BH3.  This reduction of BH4 bioavailability 
initiates the uncoupling of eNOS and augments the production of ROS further.  
Overall, the mechanisms whereby ROS interfere with NO bioavailability are 
multifactorial.   
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 ONOO- has been shown to modify proteins that are essential to normal 
vasomotor function and likely to hinder the function of endothelial cells (Haddad 
et al., 1994; van der Loo et al., 2000).  For instance, prostacyclin, important 
vasodilator, has been found its activity to be inhibited by ONOO- via the nitration 
of its tyrosine residues (Zou, Martin, & Ullrich, 1997).  Nitrosylation induced by 
ONOO- also impacts antioxidant proteins, specifically MnSOD (MacMillan-Crow, 
Crow, & Thompson, 1998; van der Loo et al., 2000).  MnSOD becomes 
inactivated after nitration of its tyrosine residues, which also contributes to an 
increase in ROS accumulation (MacMillan-Crow et al., 1998; van der Loo et al., 
2000).  Collectively, ROS can render vascular function by either degradation or 
nitrosylation of proteins.   
Aging  
Aging is one of the major risk factors for many degenerative diseases, 
especially cardiovascular disease.  A large amount of research investigates the 
physiological changes that occur with increasing age.   A major determinant of 
age-related diseases is the excess accumulation of ROS which promotes 
endothelial dysfunction.  Our understanding of why aging increases ROS 
production and promotion of endothelial dysfunction remains rudimentary.   
Reduction of Endothelial Function with Aging 
Numerous studies have examined endothelial function with aging, and all 
demonstrated with increasing age there is significant impairment in endothelium-
dependent relaxation (Csiszar et al., 2002; Donato et al., 2007; Hamilton et al., 
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2002).  There are multiple mechanisms that contribute to this observed decline in 
vascular function.   
First, with increasing age there is strong evidence that supports 
accumulation of ROS and reduction of NO bioavailability (Blackwell et al., 2004; 
Brandes, Fleming, & Busse, 2005; Brown et al., 2007; Csiszar et al., 2002; 
Didion et al., 2006; Lund et al., 2009).  As ROS increase, therefore, NO levels 
decrease, which contributes to vascular dysfunction.  NAD(P)H oxidase is the 
main source for age-related production of ROS (Adler et al., 2003; van der Loo et 
al., 2000).  There is also age-related decline of eNOS and L-arginine levels 
exacerbating ROS production (Berkowitz et al., 2003; Pacher et al., 2007).  
Antioxidant defenses are also found to decrease with age (Azhar, Cao, & 
Reaven, 1995).  This is contributed by the formation of ONOO- which is found to 
inactivate MnSOD (MacMillan-Crow et al., 1998; Yamakura & Kawasaki, 2010) 
and reduction of Nrf2 expression that induces antioxidant defenses (Ungvari et 
al., 2011).  Therefore the antioxidant defense system is overwhelmed and acts 
as a permissive mechanism to increase oxidative stress (Pacher et al., 2007; 
Sun et al., 2004).   
Oxidative stress in aged vessels also contributes to induction of pro-
inflammatory cytokines via nuclear factor-kappa B (NF-κB) activation (Csiszar, 
Ungvari, Koller, Edwards, & Kaley, 2003; Pacher et al., 2007; Ungvari, Kaley, de 
Cabo, Sonntag, & Csiszar, 2010).  These include tumor necrosis factor-α (TNF-
α), interleukin-6 (IL-6), iNOS, and vascular cytokine adhesion molecule (VCAM) 
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(Ungvari et al., 2010).  This can lead to various changes of the vessel wall such 
as age-related arterial stiffness.  Arterial stiffness is the result of increased 
fibrosis, matrix cross-linking, and thickening vessel walls and can be driven by 
transforming growth factor-beta (TGFβ), intercellular adhesion molecule-1 
(ICAM), fibronectin, and metalloproteinase-2 (MMP2) (Lakatta, 2003; Lakatta & 
Schulman, 2004; Lakatta, Wang, & Najjar, 2009).    
Reduction of Aortic Valve Function with Aging 
 The aortic valve is comprised of three cusps.  Blood is pumped 
systemically by the left ventricle where it passes through the aortic valve to the 
rest of the body.  In the healthy population, these leaflets create a tight seal 
during diastole to prevent backflow—regurgitation—into the left ventricle.  Similar 
to the vasculature, however, aortic valves are highly susceptible to age-related 
stiffening and dysfunction.   
Calcific aortic valve disease (CAVD) is the most common type of valvular 
disease that affects 5.2 million people, however, severe stenosis affects 3-4% of 
the population over the age of 65 (Beckmann, Grau, Sainger, Poggio, & Ferrari, 
2010; Freeman & Otto, 2005).   It is characterized as initial leaflet thickening to 
advance stages of calcium deposition causing obstruction of leaflet motion 
(Freeman & Otto, 2005).  As the disease progresses from sclerotic valve to 
stenotic valve a decrease of cusp separation and increase of transvalvular 
velocity across the valve during systolic pressure is observed (Weiss et al., 
2006).  The major risk factor of CAVD is increasing age (Miller et al., 2010; 
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Rosenhek et al., 2004; Stewart et al., 1997; Weiss et al., 2006).  Currently, the 
only treatment for CAVD is valve replacement.  Pharmacological interventions 
have not effectively slowed the progression of the disease (Rosenhek et al., 
2004).      
CAVD leaves calcium deposits surrounding the annulus of the valve in 
early stages of the disease, and advances to the aortic side of the leaflet as the 
disease progresses (Sucosky, Balachandran, Elhammali, Jo, & Yoganathan, 
2009).  It is believed that CAVD begins with pro-osteogenic changes that cause 
valve interstitial cells to redifferentiate into osteoblast-like cells (Rajamannan et 
al., 2003).   Bone morphogenetic protein (BMP) signaling is found to be the main 
osteogenic signaling cascade that contributes to the active calcification process 
in CAVD  (Johnson, Leopold, & Loscalzo, 2006).  BMPs are part of the TGF-β 
family and there are several BMP isoforms (Johnson et al., 2006).  BMP2 and 
BMP4 have been found to be the regulators of bone mineralization in 
cardiovascular tissue and been found consistently to be upregulated in calcified 
cardiac valves (Johnson et al., 2006).   BMP2 and BMP4 activates its 
downstream targets via the phosphorylation of smad1/5/8 proteins (Derwall et al., 
2011; Miller et al., 2010) and upregulate osteogenic transcription factors, Msx2, 
Runx2, and osterix (Franceschi & Xiao, 2003; Tyson et al., 2003).       
Aforementioned, diseases such as CAVD may also be influenced by 
increased ROS production and decreased of NO bioavailability with aging (Miller 
et al., 2010).    The major gap in the research is our understanding of the 
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mechanisms behind ROS production that contribute to endothelial 
dysfunction and valve disease with aging.  Donato et al (2007) demonstrated 
that healthy individuals’ endothelial function is impaired with age and associated 
with endothelial oxidative stress.  However, this study did not provide a 
mechanism for increased ROS and endothelial dysfunction.   
Research surrounding age-related genes, called Sirtuins, have been given 
massive amount of attention in the last five years, as a potential key to 
pathophysiological changes associated with age.   Thus far there have been 
seven sirtuin isoforms identified.  Down regulation of these genes has been 
shown to increase oxidative stress, reduce NO bioavailability, and shorten 
lifespan (Mostoslavsky et al., 2006).  For instance, SIRT1, SIRT6, and SIRT7 
knockout mice survive for a very short time and develop a progeroid phenotype 
at a very young age (Mostoslavsky et al., 2006).  Largely, the role of sirtuins 
(SIRT) is to promote genomic stability via the deacetylation of histones.  It has 
been investigated that some SIRTs, specifically SIRT3 (which is localized to the 
mitochondria), may protect against oxidative stress via upregulating MnSOD 
activity (Qiu, Brown, Hirschey, Verdin, & Chen, 2010).   Donato and Seals et al 
have also provided evidence that 1) SIRT1 may protect endothelium against 
oxidative stress and 2) SIRT1 decreases with age, which may explain this 
observed endothelial dysfunction in healthy individuals (Donato et al., 2011). 
Currently, we are not aware of research examining SIRT expression in cardiac 
valves.  
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In this study, the examination of SIRT levels may provide a novel link 
between histone acetylation, RI-RR phenomenon, and endothelia function with 
increasing age.   
So we hypothesize, that impaired endothelial and valve function with 
increasing age is the result of reductions of sirtuins and subsequent 
induction of ROS-induced ROS-release (See Figure 2).     
 
 
 
   31 
 
METHODS  
Controlled Experiment 
A controlled experimental design was the most effective way to investigate 
the effects of MnSOD-deficiency and increasing age on endothelial function in 
mice (Leedy & Ormrod, 2009).  First, mice were divided into young and aged 
cohorts that allowed examination of changes in vascular function with age.  
Second, these groups were divided into additional sub-groups based on 
genotype (MnSOD wild-type and MnSOD heterozygote).  This study design was 
the most suitable to determine interactions between the four groups.  
Based on previous findings by other investigators, in which mitochondrial 
oxidative stress induces NAD(P)H oxidase derived ROS, vice versa, mice 
deficient in MnSOD (A. E. Dikalova, Bikineyeva et al., 2010) were used.  Mice 
deficient in MnSOD have been shown to increase oxidative stress and for the 
purpose of this study it would be the most suitable model (Y. Zhang et al., 2009).  
MnSOD-deficient cohorts were generated based on the breeding scheme of 
MnSOD+/+ crossed with a MnSOD+/- to provide litters of 1:1 for each genotype.  
MnSOD null mice were not generated due to previous work has shown that 
complete knockdown of MnSOD is lethal (Y. Li et al., 1995).  These mice were 
crossed onto a C57/Bl6J background, which this background has been found to 
be the most suitable for studies of vasomotor function with aging (Andresen, 
Faraci, & Heistad, 2004; Brown et al., 2007).   Mice were littermate matched for 
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experiments when possible and wild-type littermates were used as control when 
comparing across genotypes.     
Mice were aged out to two different time points to measure an aging effect 
on vascular function and to investigate the effects of RI-RR on endothelial 
function with age.  The first group, young mice, was aged out to 3 months of age.  
This is the age where young mice are classified as sexually matured, young 
adults (Brown et al., 2007).  Old mice, the second group, were aged out to at 
least 18 months of age and no later than 22 months of age.  Past investigators 
have used similar classification for aging (Brown et al., 2007).   Mice were 
housed in climate controlled facilities under a 12 hour light/dark cycle with free 
access to water and normal chow (PicoLab Mouse Diet 5053).     
Experiments 
PCR Genotyping 
At time of wean, mice were separated based on sex.  A small piece of tail was 
collected from each mouse to perform PCR genotyping.  DNA isolation followed 
based on the Invitrogen DNA isolation mini kit.  Primers used are Primer 1 5’- 
TGTTCTCCTCTTCCTCATCTCC-3’, Primer 2 5’- ACCCTTTCCAAATCCTCAGC-
3’, Primer 3 5’- TGAACCAGTTGTGTTGTCAGG-3’, and Primer 4 5’-
TCCATCACTGGTCACTAGCC -3’ (Andresen et al., 2004) and were generated 
from the Advanced Technologies Genomics Center at Mayo Clinic, Rochester, 
MN.  Thermal cycle conditions were optimized to determine satisfactory results.  
Thermal cycle conditions are as follows: hot start of 94° for 3 minutes, and the 
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PCR conditions for 40 cycles: 94° for 20 seconds, 63° for 30 seconds, 72° for 30 
seconds.  PCR genotyping of the mice provided an internal control that the 
correct genotype of each mouse is determined correctly and accurately.   
Blood pressure 
Blood pressure was measured in both in young and old cohorts, approximately, 
one week prior to sacrifice.  Blood pressure was measured using tail-cuff 
pneumatic system (Kent Scientific).  For five consecutive days, blood pressure 
was measured to allow the mice to acclimate to the process.  The first three days 
were used as the acclimation period where the mice are to become more 
comfortable with the tail cuff procedure.  The remaining two days were used for 
analysis.  The purpose to measure blood pressure was to ensure no confounding 
variable was being observed (e.g. hypertension can induce endothelial 
dysfunction) (Rodriguez-Iturbe et al., 2007).   
Sacrifice 
Mice were sacrificed at the respective aged timepoints for instance, 3 months of 
age for the young cohort and approximately 18 months of age for the old group.  
Prior to sacrifice, mice were fasted overnight as we have found in pilot studies 
that not fasting prior to sacrifice causes high variability in glucose readings and 
vascular function.  At time of sacrifice mice were anesthetized with an 
intraperitoneal injection of pentobarbital sodium (75-100mg/kg) (Miller, Peotta et 
al., 2008).  The aorta was carefully dissected out to ensure the endothelial and 
smooth muscle is not damaged.   The aorta was then placed in cold Krebs 
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solution to have any adventitia tissue and perivascular fat removed.  The 
descending thoracic aorta was sectioned in four 2-3 mm lengths for vasomotor 
function study, whereas the arch was used for quantitative-RT PCR for the 
measurement of gene expression.  A small segment of aorta (1-2mm in length) 
was used for immunohistochemistry.    
Vasomotor Function Study 
Miller et al along with other investigators have used the following protocol as a 
way to measure aortic isometric tension and relaxation (Andresen et al., 2004; 
Brown et al., 2007; Miller, Peotta et al., 2008).  The four small segments of aorta 
were placed onto two stainless steel triangular hooks.  Organ chamber baths 
were set at physiological ambient temperature at 37°C and oxygenated with 95% 
O2 and 5% CO2 mixture.  Organ chambers were filled with Krebs solution to 
provide vessels with nutrients to be viable throughout the study.  Computer 
software from ADI Instruments recorded changes in force.  Vessels suspended in 
the baths, and were periodically tightened to 0.6 grams of tension for 
approximately 1.5 hours until all are stabilized.  At this time, 0.6 grams became 
the baseline for the future experimental curves.  Vessels were given in log doses 
of serotonin (5-HT 10-8M—10-5M; Sigma-Aldrich, St. Louis, MO) to measure 
contraction forces.  After the maximum contraction, vessels were rinsed with 
fresh Krebs solution.  Approximately, after 30 minute incubation, vessels were 
preconstricted with prostaglandin F2α (PGF2α) to approximately 60-70% of 
maximum force.  After the vessels plateaued, log doses of acetylcholine (Ach, 10-
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9M—10-4M, Sigma-Aldrich; St. Louis, MO), endothelium-dependent relaxation, 
were given to each bath at 60 second intervals.  Relaxation curve to sodium 
nitroprusside (SNP, 10-9M—10-4M, Sigma-Aldrich; St. Louis, MO), endothelium-
independent relaxation, was also measured.  Maximum constriction force of the 
vessels was measured based on doses of PGF2α (10
-7M—10-4M), before the 
proceeding dose was administered plateau of the vessels was achieved to gain a 
true representation of maximum force.   
To measure functional consequences of various inhibitory drugs, vessels were 
pre-treated with drugs prior to each acetylcholine curve. Two sections of the four 
total sections were used as a control and the other two for drug incubation for 
each mouse.  To measure effects of inhibition of NAD(P)H oxidase, treated baths 
were given 100μM (Hamilton et al., 2002) of apocynin and incubated for a total of 
30 minutes.  For specific Nox2 inhibition, 500nM (Rey et al., 2001)of gp91dstat 
unscrambled peptide 2 was administered in the treated baths, and since 
gp91dstat peptide 2 comes in two different isoforms (scrambled/unscrambled) 
the control vessels were given the scrambled peptide of gp91dstat 2.  Both were 
incubated for equal time of 30 minutes. There are two reasons for incubating the 
vessels with gp91dstat 1) to determine if ROS production is the result of Nox2 in 
the cell and 2) apocynin has been recently controversial that it could not be a 
NAD(P)H oxidase inhibitor but rather have antioxidant properties (Heumuller et 
al., 2008).   
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To analyze the results from the vasomotor function study, Lab Chart software by 
ADI Instruments will be used.  The results were tabulated in Microsoft Excel and 
displayed on charts that will have the independent variable (x-axis) dose of Ach, 
SNP, or PGF2α, and % relaxation as the dependent variable (y-axis).  
Gene Expression 
Gene expression was measured from the aortic arch in both young and old 
animals.  Aortic arch was placed in 300μL of RNA lysis buffer, 1% β-
mercapaethanol mixture.  Extraction of RNA was obtained using Invitrogen RNA 
isolation mini kit.  After RNA isolation, reverse transcriptase was performed on 
the RNA to produce cDNA (VILO synthesis, Invitrogen).  Equal amounts of RNA 
loaded were loaded into each reverse transcriptase reaction, to control for 
variability across isolations.  RNA loaded into RT reactions were based on RNA 
concentrations that was isolated (Nanodrop 2000, FisherScientific).  Quantitiative 
Real Time RT-PCR was performed on predetermined genes using a StepOne 
Plus instrument (Applied Biosystems) and changes in ΔΔCT were measured.   
As an internal control, an appropriate housekeeper was chosen to normalize the 
gene of interest to the housekeeper, again, to control for variability.   
The genes of interest can be divided into four main groups: SOD’s, NAD(P)H 
oxidases, NOS isoforms, and age-related genes.  MnSOD, CuZnSOD, and 
ecSOD were measured 1) to ensure our intervention by reducing MnSOD was 
reduced ~50% in heterozygote mice and 2) there is not a compensatory 
mechanism occurring due to reductions of MnSOD.  Second group of gene 
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expression data investigated genes that regulate antioxidant genes (Nrf2, 
FOXO1, FOXO3, FOXO4, DJ-1, and Nqo1).  Third group of gene expression 
measured are pro-oxidants: Nox1, Nox2, Nox4, and p47phox (necessary subunit of 
Nox2).  We did not measure Nox5 and Nox3 as that is not found in the species of 
mice and specifically only expressed in the brain, respectively (Drummond et al., 
2011).  Third, NOS isoforms, endothelial NOS (eNOS), inducible NOS (iNOS), 
and neuronal NOS (nNOS) were measured.  Increases of iNOS is often 
associated with inflammatory increases and oxidative stress (Csiszar et al., 2002; 
Csiszar et al., 2003).  Fourth, pro-osteogenesis genes were measured, Runx2, 
Msx2, and SP7.  Finally, age-related genes, the sirtuin isoforms (SIRT1-7) and 
Werner protein, were measured to determine if there was a reduction of any 
longevity gene expression levels with age or with MnSOD deficiency.   
Immunohistochemistry 
At time of sacrifice small segment of aorta was taken and embedded in OCT.  
After the tissue was embedded in OCT, 10μm sections were taking using a 
cryostat machine.  Sections were adhered to glass slides, consequently, were 
stained for global acetylation lysines and Histone 3 Lysine 9 (H3K9).   After 
staining, sections were imaged using confocal microscopy (Zeiss 780).  Images 
were analyzed by ImageJ software.    
Cardiac and aortic valve function 
Cardiac and aortic valve function were assessed using echocardiography (GE 
Vivid 7 ultrasound system, 13 MHz linear probe) under light isoflurane anesthesia 
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to avoid anesthesia-induced cardiodepression (heart rates were maintained 
above >475 beats/minute).  Cardiac function was evaluated from parasternal 
short-axis images at the level of the papillary muscles. Aortic valve cusp 
separation distance was measured from M-mode images taken from the 
parasternal long-axis view, and peak transvalvular velocities were measured with 
Doppler velocimetry from the suprasternal notch view. 
Ethical Considerations 
All animal experiments and protocols were approved by the Institutional Animal 
Care and Use (IACUC) at Mayo Clinic, Rochester, Minnesota.   
Validity 
This study was closely controlled by the use of controls, normalization, and 
validation.  Necessary controls were used in each experiment.  A way to control 
for variability across the mice, is that we littermate matched the mice if at all 
possible to eliminate possible variation between litters and breeders.  During 
experiments, wild-type was used as the control when comparing across 
genotypes and young mice, matched with their respective genotype, was used as 
a control when observing an age effect.  Calibration of the vasomotor function 
equipment was performed prior to each experiment.  The treatment of vessels 
during vasomotor function studies, organ chambers were divided into two groups 
(treated or non-treated) to observe a change and to have a time control bath.  
For quantitative real-time RT PCR, housekeeping genes were used to control for 
variation in the quality and quantity of RNA samples.   
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Statistical Analysis 
All data are expressed in SE±.  Main effects of age, genotype, and age-by-
genotype interactions were detected using two-way ANOVA testing.  Subsequent 
comparisons across groups were made using Bonferroni-corrected t-tests.   
Based on previous preliminary data, we anticipated that 15 animals per group 
would be sufficient to detect change with pre-determined power >0.80 when 
α=0.05.     
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RESULTS 
Antioxidant gene expression in aorta.  As expected, expression of MnSOD 
was reduced by ~50% in MnSOD+/- mice compared to MnSOD+/+ mice in both 
young and old groups.  MnSOD-deficiency did not affect expression of CuZnSOD 
and ecSOD in young mice, nor did it affect age-related reductions in these genes 
(Figure 3A-C).   
Antioxidant gene expression in aortic valve.  As expected, expression of 
MnSOD was reduced by ~50% in aortic valves from MnSOD+/- mice compared to 
age-matched MnSOD+/+ mice.  Expression of CuZnSOD and ecSOD was 
markedly reduced by aging, and these reductions were not affected by MnSOD 
deficiency (Figure 3D-F).  
Genes regulating antioxidant responses in aorta.  Expression of FOXO1, 
FOXO3, and FOXO4 were significantly reduced with aging, but these changes 
were not altered by MnSOD-deficiency.  Nrf2 was slightly decreased with age but 
not affected by MnSOD-deficiency.  Nqo1 and DJ-1 were relatively unchanged 
across both age and genotype groups (Figure 4A-B and Appendix 1A-D).   
Genes regulating antioxidant responses in aortic valve.  Expression of 
FOXO1, FOXO3, and FOXO4 was reduced in aortic valve with aging and, similar 
to aorta, these changes were not altered by MnSOD-deficiency.  Reduction of 
MnSOD also did not affect age-related declines in Nrf2 or DJ-1 (Figure 4C-D and 
Appendix 1E-H).   
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Pro-oxidant and pro-inflammatory gene expression in aorta. Similar to 
MnSOD+/+ mice, expression of Nox1 was not detectable in aorta from MnSOD+/- 
mice, and expression of Nox4 was not altered with aging in either group (Figure 
5B).  Expression of Nox2 in aorta was elevated in both young and old MnSOD+/- 
mice compared to age-matched MnSOD+/+ mice (Figure 5A), and was paralleled 
by changes in p47phox expression (Appendix 2A).  Changes in expression of TNF-
α were similar between MnSOD+/+ and MnSOD+/- mice within and across age 
groups (Appendix 3C).     
Pro-oxidant and pro-inflammatory gene expression in aortic valve.  In aortic 
valves from MnSOD+/- mice, Nox4 was decreased by aging to a similar extent to 
that observed in MnSOD+/+ mice (Figure 5D).  Unlike aorta, however, expression 
of Nox2 was not increased in MnSOD+/- mice compared to age-matched 
MnSOD+/+ mice (Figure 5C).  Expression of ICAM, VCAM, and TNF in young 
and aged MnSOD+/- mice were similar to levels observed in their age-matched 
MnSOD+/+ littermates (Appendix 3D-F).     
Changes in NOS isoform expression in aorta.  In aorta, eNOS expression was 
not affected by aging in MnSOD+/+ or MnSOD+/- mice.  Similarly, expression of 
iNOS was not significantly affected by aging in MnSOD+/+ or MnSOD+/- mice 
(Table 1).   
Changes in NOS isoform expression in aortic valve.  MnSOD-deficiency did 
not alter eNOS expression in aortic valves from young mice, and MnSOD+/- mice 
had similar age-related reductions in eNOS compared to MnSOD+/+ littermates.  
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Age-related increases in iNOS expression in aortic valve were similar between 
MnSOD+/+ and MnSOD+/- mice.  Expression of nNOS was not detectable in 
young or aged MnSOD+/- mice (Table 1).    
Aging- and senescence-related gene expression in aorta.  There were 
significant age-related decreases of SIRT1, SIRT2, and WRN expression in aorta 
(Figure 6A-B and Appendix 4A).  SIRT5, SIRT6, and SIRT7 were significantly 
increased with age, but were not affected by reduction of MnSOD (Figure 6E-G).  
Expression of cyclin-dependent kinase inhibitor 2a (CDKN2A) was significantly 
increased in aged mice, but was not affected by reduction of MnSOD (Figure 
6H).  
Aging- and senescence-related gene expression levels in aortic valve.  
Sirtuin expression was not affected by MnSOD deficiency in young mice, and 
age-related reductions in SIRT1, SIRT2, SIRT3, SIRT4, SIRT6, and Wrn (Figure 
6I-L, N and Appendix 4B) were similar in aortic valves from MnSOD+/- and 
MnSOD+/+ mice.   Expression of SIRT5, however, was significantly increased in 
aged MnSOD+/- mice compared to young MnSOD+/- mice (Figure 6M).  
Expression of CDKN2A was profoundly increased in aged mice and was not 
affected by MnSOD deficiency (Figure 6P).    
Vasomotor Function Results 
Vascular relaxation to acetylcholine was significantly reduced in aged 
MnSOD+/+ mice compared to young MnSOD+/+ mice.  Inhibition of NAD(P)H 
oxidase with apocynin did not affect responses to acetylcholine in young 
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MnSOD+/+ mice, and significantly improved responses to acetylcholine in aged 
MnSOD+/+ mice (Figure 7A-B).  Responses to sodium nitroprusside were 
unaffected by aging (Table 2).  Maximum tension in response to PGF
 was 
augmented in aged MnSOD+/+ mice compared to young MnSOD+/+ mice (Table 
2). 
Relaxation to acetylcholine was not impaired in aorta from young MnSOD+/- mice 
compared to MnSOD+/+ littermates, and age-related impairments in endothelial 
function were similar in aorta from the two genotypes of mice.  In contrast, 
NAD(P)H oxidase inhibition significantly impaired responses to acetylcholine in 
both young and old MnSOD+/- mice (Figure 7A-B).  Similar responses were 
observed following incubation with gp91ds-TAT, an inhibitor of the Nox2 catalytic 
subunit (Appendix 5).  Responses to sodium nitroprusside were similar between 
MnSOD+/- and MnSOD+/+ mice in both age groups (Table 2).  Responses to 
PGF
  in MnSOD+/- mice were similar to those observed in MnSOD+/+ mice in 
both age groups (Table 2).   
Aortic Valve Function 
Aortic valve cusp separation was not significantly different between young and 
old MnSOD+/+ mice, and were not altered by MnSOD haploinsufficiency (Figure 
7C).  Similarly, peak transvalvular velocity was largely unchanged between 
groups (Figure 7D).  We also did not detect differences in the prevalence of 
aortic valve regurgitation between the two groups.   
Cardiac Function 
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Heart rates under anesthesia were maintained >500 bpm and there were no 
differences between groups (Appendix 6A).  Ejection fraction was significantly 
reduced with aging in both genotypes (Appendix 6B).  End-diastolic dimensions 
and end-systolic dimensions were significantly increased in aged mice MnSOD+/+ 
mice, and these changes were not affected by MnSOD haploinsufficiency 
(Appendix 6C-D).    
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DISCUSSION 
The main findings of this study are: 1) there are dramatically different 
transcriptional responses to aging in aorta and aortic valve, 2) the functional 
consequences of NAD(P)H oxidase-derived radicals are critically dependent on 
mitochondrial antioxidant levels in aorta in both young and aged mice, 3) despite 
apparent deleterious molecular changes, aortic valve function is remarkably well 
preserved with increasing age in mice, and 4) reductions in mitochondrial 
antioxidant capacity amplify and modulate, but do not independently initiate, 
osteogenic signaling in vascular smooth muscle cells.   
Transcriptional responses to aging in aorta 
In aorta from wild-type mice, we found that aging was associated with changes in 
transcriptional patterns that favored a pro-oxidative environment.  Specifically, 
levels of ecSOD and CuZnSOD were significantly reduced and expression of 
Nox2 was significantly increased in aorta from aged wild-type mice.  This 
reduced antioxidant capacity is consistent with data from previous reports in 
aging mice, and may be in part due to age-associated reductions the 
transcription factors DJ-1 and members of the FOXO family, ultimately resulting 
in reductions in Nrf2 (Collins et al., 2009; Ungvari et al., 2011).  NAD(P)H 
oxidase-derived reactive oxygen species have also been shown to be increased 
with aging, and have also been shown to play a key role in limiting nitric oxide 
bioavailability (Hamilton et al., 2002; Podlutsky et al., 2010) and promoting 
fibrosis in aged conduit vessels (Lakatta et al., 2009).  When combined with age-
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related reductions in endothelial nitric oxide synthase and SIRT1 expression, 
these molecular changes would be expected to strongly favor perivascular 
fibrosis and vascular stiffening with aging (Donato et al., 2011).     
In the present study we found that Nox2 expression was increased in young and 
old MnSOD-deficient mice compared to their wild-type littermates.  This finding is 
consistent with work from previous work in cultured endothelial cells 
demonstrating a positive feedback loop between mitochondria and NAD(P)H 
oxidase-derived ROS (A. E. Dikalova, Bikineyeva et al., 2010)—a phenomenon 
more commonly referred to as ROS-induced ROS release.  This pro-oxidative 
environment did not, however, augment age-related reductions in expression of 
endothelial nitric oxide synthase or sirtuin enzymes, nor did these changes 
augment age-associated increases in pro-fibrotic or pro-calcific gene expression 
(see online supplement).  Thus, these data provide compelling evidence against 
the “oxidative stress hypothesis of cardiovascular aging” (Pedruzzi et al., 2004), 
and instead support a working model in which ROS-induced ROS-release 
initiated by losses in mitochondrial antioxidant capacity is not a primary driver of 
molecular changes promoting age-related vascular disease, and are instead 
likely to alter vasomotor function in a highly context-dependent manner in aorta.   
Transcriptional responses to aging in aortic valve 
Similar to our findings in aorta, our data from aortic valves suggest that age-
related reductions in antioxidant expression in wild-type mice also favor a pro-
oxidative environment.  Unlike aorta, however, expression of NAD(P)H oxidase 
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subunits was not increased with aging, and expression of Nox4 was significantly 
decreased.  To our knowledge, these are the first data characterizing changes in 
pro- and anti-oxidant enzymes in aged (but functionally normal) aortic valves, 
and the first to identify a fundamental difference in expression of redox-related 
genes in aorta and aortic valve.  While these age-related reductions in 
antioxidant gene expression are remarkably similar to those observed in stenotic 
aortic valves (Miller, Chu et al., 2008), we did not observe increases in pro-
fibrotic or pro-calcific gene expression in aortic valves from aged MnSOD+/+ mice.  
Taken together with our data from aorta, it is possible that activation of pro-
fibrotic and pro-calcific signaling is linked to NAD(P)H oxidase activation in wild-
type mice.  This postulate is consistent from findings in myocardium, where 
upregulation of Nox4 appears to be a critical regulatory event in the induction of 
pro-fibrotic signaling cascades (Rey et al., 2001), and from data in aorta, where 
administration of exogenous antioxidants reduces NAD(P)H oxidase-derived 
ROS and attenuates pro-fibrotic signaling (Cai & Harrison, 2000; Fleenor, Seals, 
Zigler, & Sindler, 2011).   
The lack of an increase in pro-fibrotic and pro-calcific gene expression in aortic 
valves from MnSOD+/+ mice was particularly surprising given the observation that 
expression of multiple sirtuin isoforms was markedly reduced in aortic valves with 
aging.  Sirtuin deacetylases are emerging as important regulators of gene 
expression and function in the cardiovascular system.  In particular, SIRT1 has 
been shown to inhibit TGF-induced gene expression and fibrosis in aorta and 
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myocardium with aging (Roger et al., 2011), and has been shown to be critical for 
maintenance of nitric oxide synthase function (A. Dikalova et al., 2005; Hamilton 
et al., 2002).  Collectively, age-associated induction of valvular fibrosis and 
calcification may well involve a complex interplay and balance between activation 
of TGF superfamily signaling, increases in NAD(P)H oxidase-derived ROS, and 
reductions in sirtuin levels.   
In aortic valves from MnSOD+/- mice, we did not observe significant changes in 
NAD(P)H oxidase expression.  Importantly, these are the first data suggesting 
that mitochondria-initiated ROS-induced ROS release may occur in a highly 
tissue specific manner, does not appear to occur in the aortic valve, and 
represents a fundamental difference in the molecular responses to aging and 
increased mitochondrial oxidative stress in aorta and aortic valve.  Similar to our 
findings in aorta from MnSOD+/- mice, however, MnSOD deficiency did not elicit 
further reductions in sirtuin expression or increases in pro-fibrotic signaling in 
aortic valves from young or aged mice.  Collectively, these data suggest that 
reductions in MnSOD are not likely to be a primary driver of pro-fibrotic or pro-
calcific gene expression in aortic valves from young or aged mice, and instead 
may play a modulatory or permissive role when pro-fibrotic or pro-calcific stimuli 
are present.       
Functional consequences of aging and MnSOD deficiency in aorta 
We observed significant reductions in endothelial function with aging in wild-type 
mice that were largely reversible by inhibition of NAD(P)H oxidase with apocynin 
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or the Nox2 inhibitor gp91ds-tat.  This is consistent with previous work 
demonstrating that NAD(P)H oxidase (and Nox2-derived radicals in particular) 
are important contributors to age-related declines in endothelial function (Csiszar 
et al., 2002; Hamilton et al., 2002; Podlutsky et al., 2010).   
Consistent with previous reports, we also found that endothelial function was not 
impaired in young MnSOD+/- mice compared to their MnSOD+/+ littermates 
(Andresen et al., 2004; Brown et al., 2007).  We were, however, somewhat 
surprised to find that endothelial function in aged mice was not further impaired 
by MnSOD haploinsufficiency, as other groups have reported greater impairment 
of endothelial function in aged MnSOD+/- mice (Andresen et al., 2004; Brown et 
al., 2007).  One potential explanation for this difference in findings is that our 
“aged” mice were significantly younger than those used in previous studies (~18 
months old versus 24+ months old).  Differences in animal husbandry, 
cumulative environmental stress, and diet may also significantly impact metabolic 
state and endothelial function with aging (S. I. Dikalov et al., 2008).   
A major novel finding of this study, however, is that inhibition of NAD(P)H 
oxidase significantly impaired endothelial function in both young and aged 
MnSOD+/- mice.  This finding was contrary to our hypothesis that ROS-induced 
ROS-release would impair endothelial function in aorta.  Numerous studies have 
shown that, under a variety of stressed conditions, Nox2 or mitochondria-derived 
radicals impair endothelial function via reductions in NO bioavailability (S. 
Dikalov, 2011; Donato et al., 2007; Landmesser et al., 2003).  Conversely, 
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several studies have reported that mitochondria-derived H2O2 elicits vasodilation 
in coronary arteries (Forstermann, 2010; Furchgott et al., 1987; Gongora et al., 
2006; Y. Zhang et al., 2009), and that Nox4-derived ROS may play a central role 
in maintaining nitric oxide bioavailability (Drummond et al., 2011).  Taken 
together, our data support a working model in which the vasomotor 
consequences of increased hydrogen peroxide levels are dependent not only on 
the level of physiological stress an organism is facing, but also on mitochondrial 
antioxidant status.   
Functional consequences of aging and MnSOD deficiency in aortic valve 
Aortic valve function in wild-type mice was unchanged with increasing age.  
Somewhat surprisingly, MnSOD deficiency did not impact aortic valve function 
compared to wild-type mice in both age groups.  We anticipated that losses in 
mitochondrial antioxidant capacity would negatively impact aortic valve function 
with aging, due to previous studies suggesting that increases in oxidative stress 
are strongly associated with calcification in tissue from humans with calcific aortic 
valve disease (Miller, Chu et al., 2008), and experimental data suggesting that 
increases in oxidative stress and reductions in nitric oxide bioavailability 
accelerate cardiovascular cell calcification in vitro (Arnal, Dinh-Xuan, Pueyo, 
Darblade, & Rami, 1999; Touyz & Briones, 2011).  A possible explanation for the 
contrast in findings is that the mice used in this study were not exposed to 
significant exogenous stressors (e.g., high fat diet, hypertensive stress, etc.), and 
the combination of hypercholesterolemia and oxidative stress are needed to 
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induce aortic valve disease in aging mice (Bengtsson et al., 2003; A. E. Dikalova, 
Gongora et al., 2010; Niu et al., 2010).     
Conclusions 
Collectively, our data demonstrate that the transcriptional responses and 
phenotypes elicited by aging and alterations in mitochondrial antioxidant capacity 
differ dramatically between aorta and aortic valve.  Furthermore, the functional 
consequences of NAD(P)H-derived ROS and ROS-induced ROS-release appear 
to be critically dependent upon mitochondrial antioxidant capacity in aorta from 
“unstressed” mice.  These data support a working model in which age-related 
reductions in mitochondrial antioxidant capacity are an important modulator, but 
not primary driver, of age-related cardiovascular disease.   
   52 
 
TABLES 
Table 1.  Effects of aging and MnSOD-haploinsufficiency on expression of nitric oxide synthase 
isoforms. ** Denotes significant main effect of age with p-value < 0.05.   Values are means ± SE; 
n = 4-14 mice/group. 
             
  Aorta  Aortic Valve 
  Young  Old  Young  Old 
  WT HET  WT HET  WT HET  WT HET 
Nitric 
Oxide 
Synthase 
Isoforms 
           
 eNOS 1.0±0.1 1.1±0.1  0.9±0.1 0.9±0.1  1.0±0.1 1.0±0.1  0.7±0.2** 0.7±0.1** 
 iNOS 1.0±0.3 0.9±0.3  1.9±0.7 1.4±0.3  1.0±0.3 0.95±0.3  3.7±0.8** 5.0±1.0** 
 nNOS n.d. n.d.  n.d. n.d.  n.d. n.d.  n.d. n.d. 
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Table 2.  Effects of aging and MnSOD-haploinsufficiency on vasomotor function in aorta.  ** 
Denotes significant main effect of age with p-value < 0.05.  Values are means ± SE; n = 8-23 
mice/group. 
        
  Aorta  
  Young  Old  
  WT HET  WT HET  
Relaxation 62±3% 62±1%  49±3%** 43±3%**  
 MRACH       
 EC50ACH       
 MRSNP 90±2% 91±2%  94±2% 96±1%**  
        
Constriction       
 Peak Tension (PGF2) 1.2±0.04 1.1±0.06  1.78±0.1**  1.74±0.1**  
 Peak Tension (5HT) 0.68±0.07 0.68±0.07  0.90±0.04** 0.86±0.04**  
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FIGURES 
 
 
Figure 1 ROS-Induced ROS-Release Phenomenon 
 
In vitro studies have shown that production of ROS by NAD(P)H oxidase and 
mitochondria may self-perpetuate itself, creating a vicious cycle of ROS 
production.  
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Figure 2: Working Model 
 
Aging is a major risk factor for various cardiovascular diseases, specifically, 
endothelial dysfunction and valve disease.  Our hypothesis is that impaired 
endothelial and valve function with increasing age is the result of reductions of 
sirtuins and subsequent induction of ROS-induced ROS-release. 
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Figure 3:  Antioxidant gene expression levels legend  
(Fig 3A and 3D)  MnSOD expression was reduced by ~50% in heterozygote mice 
(p < 0.01) in both aorta and aortic valve tissues.  (Fig3B-C and Fig3E-F) There 
was no increase of other antioxidant mechanisms in both aorta and aortic valve 
due to reductions of MnSOD.  However, CuZnSOD and ecSOD were significantly 
decreased with increasing age in both aorta and aortic valve.  * Denotes 
significant main effect of genotype with p-value <0.05.  ** Denotes significant main 
effect of age with p-value < 0.05.   # Denotes significant differences between groups with 
p-value<0.05. Values are means ± SE; n = 4-14 mice/group.  
Figure 3A: MnSOD expression in aorta. 
Figure 3B: CuZnSOD expression in aorta. 
Figure 3C: ecSOD expression in aorta. 
Figure 3D: MnSOD expression in aortic valve. 
Figure 3E: CuZnSOD expression in aortic valve. 
Figure 3F: ecSOD expression aortic valve. 
Composite of Figure 3. 
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Figure 3A: MnSOD expression in aorta. 
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Figure 3B: CuZnSOD expression in aorta. 
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Figure 3C: ecSOD expression in aorta. 
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Figure 3D: MnSOD expression in aortic valve. 
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Figure 3E: CuZnSOD expression in aortic valve. 
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Figure 3F: ecSOD expression in aortic valve. 
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Figure 3: Composite 
.
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Figure 4: Gene expression of genes regulating antioxidants legend. 
  Increasing age causes a significant decrease in FOXO-4 and Nrf2 gene 
expression, but MnSOD haploinsufficiency does not have an effect.  .  ** Denotes 
significant main effect of age with p-value < 0.05.   # Denotes significant 
differences between groups with p-value<0.05. Values are means ± SE; n = 4-14 
mice/group. 
Figure 4A: FOXO-4 expression in aorta. 
Figure 4B: Nrf2 expression in aorta. 
Figure 4C: FOXO-4 expression in aortic valve. 
Figure 4D: Nrf2 expression in aortic valve. 
Composite of Figure 4. 
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Figure 4A: FOXO-4 expression in aorta. 
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Figure 4B: Nrf2 expression in aorta. 
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Figure 4C: FOXO-4 expression in aortic valve. 
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Figure 4D: Nrf2 expression in aortic valve. 
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Figure 4: Composite 
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Figure 5:  Expression of NAD(P)H oxidase subunits legend. 
  (A-D) Observe the large differences of Nox2 and Nox4 mRNA expression levels 
across tissues.  *Denotes significant main effect of genotype with p-value <0.05.  
** Denotes significant main effect of age with p-value < 0.05.   # Denotes 
significant differences between groups with p-value<0.05. Values are means ± 
SE; n = 4-14 mice/group.  Nox, NAD(P)H oxidase. 
Figure 5A: Nox2 expression in aorta. 
Figure 5B: Nox4 expression in aorta. 
Figure 5C: Nox2 expression in aortic valve. 
Figure 5D: Nox4 expression in aortic valve. 
Composite of Figure 5. 
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Figure 5A: Nox2 expression in aorta. 
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Figure 5B: Nox4 expression in aorta. 
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Figure 5C: Nox2 expression in aortic valve. 
   74 
 
 
Figure 5D: Nox4 expression in aortic valve. 
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Figure 5: Composite 
   76 
 
 
Figure 6:  Expression of age-related genes legend. 
Note the largely unchanged Sirt expression in aorta (A-G) compared to aortic 
valve (I-O), whereas six of the seven Sirt isoforms were significantly reduced with 
age.  Also, note MnSOD- haploinsufficiency largely does not impact SIRT 
expression.  Marker of cellular senescence (Fig6H and 6O), CDK2NA, was 
significantly increased with age in both aorta and aortic valve. ** Denotes 
significant main effect of age with p-value < 0.05.   # Denotes significant 
differences between groups with p-value<0.05. Values are means ± SE; n = 4-14 
mice/group.   Sirt, sirtuin.    
Figure 6A: Sirt1 expression in aorta. 
Figure 6B: Sirt2 expression in aorta. 
Figure 6C: Sirt3 expression in aorta. 
Figure 6D: Sirt4 expression in aorta. 
Figure 6E: Sirt5 expression in aorta. 
Figure 6F: Sirt6 expression in aorta. 
Figure 6G: Sirt7 expression in aorta. 
Figure 6H: CDKN2A expression in aorta. 
Figure 6J: Sirt2 expression in aortic valve. 
Figure 6I: Sirt1 expression in aortic valve. 
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Figure 6K: Sirt3 expression in aortic valve. 
Figure 6L: Sirt4 expression in aortic valve. 
Figure 6N: Sirt6 expression in aortic valve. 
Figure 6M: Sirt5 expression in aortic valve. 
Figure 6O: Sirt7 expression in aortic valve. 
Figure 6P: CDKN2A expression in aortic valve. 
Composite of Figure 6. 
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Figure 6A: Sirt1 expression in aorta. 
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Figure 6B: Sirt2 expression in aorta. 
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Figure 6C: Sirt3 expression in aorta. 
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Figure 6D: Sirt4 expression in aorta. 
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Figure 6E: Sirt5 expression in aorta. 
   83 
 
 
Figure 6F: Sirt6 expression in aorta. 
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Figure 6G: Sirt7 expression in aorta. 
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Figure 6H: CDKN2A expression in aorta. 
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Figure 6I: Sirt1 expression in aortic valve. 
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Figure 6J: Sirt2 expression in aortic valve. 
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Figure 6K: Sirt3 expression in aortic valve. 
   89 
 
 
Figure 6L: Sirt4 expression in aortic valve. 
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Figure 6M: Sirt5 expression in aortic valve. 
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Figure 6N: Sirt6 expression in aortic valve. 
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Figure 6O: Sirt7 expression in aortic valve.  
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Figure 6P: CDKN2A expression in aortic valve.  
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Figure 6: Composite 
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Figure 7: Aorta and Aortic Valve Function legend.   
(A-B)  Vasomotor responses to acetylcholine (ACh) in both young and old mice.  
Vessels were treated with vehicle or with apocynin, NAD(P)H oxidase inhibitor.  
Note the relaxation to ACh is significantly impaired in MnSOD+/- mice after 
incubation of apocynin.  *Denotes significance in treatment group vs. control 
group.  p-value < 0.05.  (C-D) Measurements of aortic valve function by 
echocardiography. Values are means ± SE; n = 8-23 mice/group. Ach, 
acetylcholine. 
Figure 7A: Aorta vasomotor function in young mice.  
Figure 7B: Aorta vasomotor function in old mice.  
Figure 7C: Aortic valve function measurement of cusp separation. 
Figure 7D: Aortic valve function measurement of peak velocity.   
Composite of Figure 7
   96 
 
 
Figure 7A: Aorta vasomotor function in young mice. 
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Figure 7B: Aortic vasomotor function in old mice. 
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Figure 7C: Aortic valve function measurement of cusp separation. 
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Figure 7D: Aortic valve function measurement of peak velocity. 
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APPENDIX 
 
 
 
Appendix 1: Gene expression of genes regulating antioxidants. 
 ** Denotes significant main effect of age with p-value < 0.05.   # Denotes 
significant differences between groups with p-value<0.05. Values are means ± 
SE; n = 4-14 mice/group 
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Appendix 2: p47phox gene expression of aorta and aortic valve.   
** Denotes significant main effect of age with p-value < 0.05.   # Denotes 
significant differences between groups with p-value<0.05. Values are means ± 
SE; n = 4-14 mice/group. 
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Appendix 3: Pro-inflammatory gene expression of aorta and aortic valve. 
    ** Denotes significant main effect of age with p-value < 0.05.   # Denotes 
significant differences between groups with p-value<0.05. Values are means ± 
SE; n = 4-14 mice/group.   
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Appendix 4: Werner protein gene expression levels of aorta and aortic 
valve.  
** Denotes significant main effect of age with p-value < 0.05.   # Denotes 
significant differences between groups with p-value<0.05. Values are means ± 
SE; n = 4-14 mice/group. 
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Appendix 5: Vasomotor responses after incubation of gp91dstat peptide 2 
(500nM).  
 Treatment of gp91dstat peptide 2, a specific Nox2 inhibitor, caused significant 
impairment of young MnSOD+/- mice. * Denotes significance in treatment group 
vs. control group.  p-value < 0.05.  Values are means ± SE; n = 7 mice/group. 
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Appendix 6: Cardiac Function.   
Values are means ± SE; n = 12-23 mice/group.  ** Denotes significant age effect 
with p-value < 0.05. # Denotes significance p-value<0.05. 
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Appendix 7:  Pro-calcific gene expression of aorta and aortic valve.  
** Denotes significant main effect of age with p-value < 0.05.   # Denotes 
significant differences between groups with p-value<0.05. Values are means ± 
SE; n = 4-14 mice/group. N.D., not-detectable. 
               
               
               
               
                
